Fund+
Venture capitalLeuven · Series A–Series B · 11 people tracked
Investment thesis
Fund+ is an open-ended fund dedicated to long-term equity investment in innovative Life Sciences companies, with a particular focus on Belgium. It aims to create sustainable shareholder value, help build a leadership position within the Life Sciences sector, and generate meaningful, beneficial societal impact.
Source: firm website, verified Aug 3, 2026.
Team · 11 people
from the firm's website & public directories
What they invest in
from 9 of 20 portfolio companiesBiotech ×8Healthtech ×4Medical Devices ×4Digital Health ×2Deep Tech ×1Hardware ×1
HQs:Netherlands×1United States×1
Investments · 20 tracked
founders shown can be your intro pathBiotechnology company developing orally available therapies for chronic inflammatory and autoimmune diseases.
BiotechNew York, US
Hella Kohlhof(Executive Officer)Andreas Muehler(Executive Officer)Daniel Vitt(Executive Officer, Director)JASON TARDIO(Executive Officer)GLENN WHALEY(Executive Officer)INDERPAL SINGH(Executive Officer)
Astrivax develops virus-targeted immunotherapies using its Launch-iT platform to eliminate cancer-causing viruses before they lead to disease, with an initial focus on HPV-driven cancers.
BiotechHealthtech
EPICS Therapeutics develops RNA epigenetics-based cancer treatments, focusing on METTL3 inhibitors for cancers including non-small cell lung cancer, pancreatic cancer, ovarian cancer, and colorectal cancer where existing therapies are insufficient.
BiotechDigital HealthMedical Devices
EyeD Pharma is a clinical-stage pharmaceutical company developing sustained-release micro-implants and complex therapeutics for ophthalmic diseases such as glaucoma, dry eye, and back-of-the-eye conditions.
BiotechHealthtechMedical Devices
Indigo is developing an implantable continuous multi-metabolite monitoring (CMM) sensor based on silicon photonics that measures metabolites such as glucose, ketone, and lactate in real time, with data shown via a smartphone app.
Digital HealthHardwareMedical Devices
Danaë Delbeke(CTO and Founder)
Clinical-stage biotech developing therapies for orphan CNS diseases; lead program MIN-102 in trials for X-linked Adrenoleukodystrophy and Friedreich's Ataxia.
TargED Biopharmaceuticals is a Netherlands-based biotechnology company developing first-in-class biological drugs that use small antibodies (VHH) to deliver enzymes to sites of thrombosis for targeted thrombolysis.
BiotechMedical Devices
Germany-based clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs) for oncology, acquired by Gilead Sciences for $3.15 billion upfront plus up to $1.85 billion in contingent payments.
Exits · 2
IPOs and acquisitions across the tracked portfolioImmunicNASDAQ: IMUXTubulis GmbHacq. by Gilead Sciences
Frequently asked questions
- What stage does Fund+ invest at?
- Fund+ invests at the Series A, Series B stages.
- What is Fund+'s typical check size?
- Fund+ typically writes checks of $5.5M – $16.5M.
- What sectors does Fund+ focus on?
- Fund+ focuses on Biotech, Healthtech, Impact & Social Good, Longevity, Medical Devices.
- Where is Fund+ located?
- Fund+ is headquartered in Leuven, BE.
Similar investors
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
The Dementia Discovery Fund (DDF), managed by SV Health Investors, is a family of specialized venture capital funds investing exclusively in companies developing or enabling novel therapeutics for dementia, including Alzheimer's Disease.
DOMiNO Ventures is a venture capital firm backing high-tech, pure-digital, globally ambitious founders with roots in Eastern Europe, Central Asia, and the Caucasus, including diaspora talent. It also runs the BetterFuture AI Acceleration Program and pursues impact-oriented Better Future Goals.
LIFTT is a venture capital holding company focused on deep tech technologies, using an operational, multi-vertical approach aimed at generating impact. It works to transform scientific research into high-impact companies, accelerating the path from lab to market.